Fatigue and Sleep Disturbances


Guiding Priniciple:

Fatigue is a very common symptom in end-stage kidney disease and it is often multifactorial. Treat the patient's tiredness and/or daytime drowsiness if it is affecting their quality of life.

  • Exercise (if appropriate)
  • Nutrition and hydration management
  • Cognitive and psychological approaches (eg. relaxation therapy, hypnosis, stress management, delegating and setting limits)
  • Complementary treatments such as acupressure/acupuncture (no high quality evidence to support this; no lasting adverse effects)
  • Energy Conservation Strategies (See: Tiredness Patient Handout)
  • Promoting good sleep hygiene (See: Sleep Patient Handout)
  • Incorporate relaxation techniques
  • Consider suggesting to your patient:
    • Wake up at the same time every morning
    • Do not go to bed until you feel sleepy
    • Do not “try” to fall asleep
    • Avoid napping during the day
    • Avoid caffeine in the evening
    • Save your bedroom for sleep (and sex) only
    • Leave your day’s dilemmas at the door

Reassess medications prescribed for the treatment of insomnia after 2-4 weeks. Avoid OTC sleep aids and benzodiazepines if possible.

Consider low-dose gabapentin or pregabalin (particularly if the patient has concomitant symptoms of neuropathic pain, RLS, or uremic pruritus ):


  • 50-100* mg PO nightly. If not effective, it can be further titrated by 100 mg every 7 nights to a maximum of 300 mg PO qhs. It should be taken 2-3 hours before bed due to delay of peak onset.
  • Note that gabapentin is not commercially available in 50 mg capsules, but can be compounded for patients if the recommended low starting dose is desired.
  • The most common side effects are drowsiness, dizziness, confusion, and fatigue. Peripheral edema may also be a side effect.


  • Similar to gabapentin, but more expensive and not covered by Seniors’ or Basic Alberta Blue Cross plans. Other private plans may cover the cost.
  • Pregabalin can be initiated at 25 mg PO nightly and titrated by 25 mg every 7 nights to a maximum of 75 mg PO qhs. It should be taken 2 hours before bedtime.
  • Potential side effects are similar to those of gabapentin.

If ineffective, cautiously consider:

Mirtazapine (Remeron)

  • 7.5 mg PO at bedtime (not if taking Tramadol or antidepressants)


  • 10 mg PO at bedtime (monitor carefully for anticholinergic side effects and cardiac arrhythmias)


  • 3.75-5 mg PO at bedtime for short term use


  • 2-5 mg PO at bedtime (although the evidence is somewhat limited and inconclusive)

Special considerations at End of Life:

  • As a patient’s condition deteriorates, certain non-pharmacological interventions will become less realistic (eg. exercise). Energy conservation and restoration will become of utmost importance.
  • Ensure that appropriate supports are in place to assist with activities of daily living and that nursing care is available as needed.
  • Drowsiness may increase as the end of life approaches due to disease progression (and/or medications.) Some patients and families may even prefer increased sleepiness if the patient remains comfortable.

Warning, this site doesn't support the web browser version you are using.

Thus, certain functions may be missing or appear to be broken. Please considering updating your browser to improve your web experience.